A fully funded P3 in progress.
Significantly back ended deal.
'Low bar' end points when taking P2 results into account.
ROW rights still up for grabs.
A reputedly superior 'baby brother' drug in the background, now funded through P2 trials for 3 rare diseases.
Realistic chance that the tech could cover the autism spectrum.
IS THIS A DREAM INVESTMENT?
For me, the answer is a big fat NO. Why?
Because the market cap has been destroyed and the register set up to profit an invading cancer intent on a low ball takeover.
A total failure of management.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$19.64 |
Change
0.040(0.20%) |
Mkt cap ! $2.480B | |||
| Open | High | Low | Value | Volume |
| $19.40 | $19.72 | $19.12 | $10.95M | 559.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 531 | $19.62 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.65 | 235 | 2 |
View Market Depth
| Last trade - 16.17pm 17/09/2025 (20 minute delay) ? |
| NEU (ASX) Chart |